Effects of Long-Term Testosterone Therapy on Patients with “Diabesity”: Results of Observational Studies of Pooled Analyses in Obese Hypogonadal Men with Type 2 Diabetes
Table 2
Comorbidities and concomitant medications at baseline for 156 obese hypogonadal men with type 2 diabetes mellitus treated with testosterone undecanoate for up to 6 years.
Comorbidities
Hypertension
153 (99.4%)
Type 2 diabetes
156 (100%)
Dyslipidaemia
156 (100%)
Coronary artery disease
37 (23.7%)
Myocardial infarction
19 (12.2%)
Concomitant medications for diabetes at baseline
Metformin
36 (23.1%)
Insulin
25 (16%)
Sulfonylurea
8 (5.1%)
Acarbose
2 (1.3%)
Antidiabetic drugs not further specified
51 (32.7%)
Total antidiabetic drugs
122 (78.2%)
No diabetes drugs (including 2 patients who were “prescribed” a diet)
29 (18.6%)
No information available
9 (5.8%)
Other concomitant medication categories at baseline
